Xavier G. Farre

Badalona, CT, ES 
Badalona, CT, ES 

Overview

Xavier Farre practices practicing medicine in Badalona, Spain.

His clinical expertise encompasses Lymphangioleiomyomatosis, Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Prostate Cancer, and Prostatectomy.

He is actively involved in clinical research, co-authoring 54 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Badalona, CT 08916, Spain
Other Locations
Lleida, CT 25006, Spain
CT, Spain
Barcelona, CT 08916, Spain
Frias, CL 08916, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 3
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: October 25, 2022
Intervention Type: Drug
Study Drug: Neratinib+Endocrine Therapy
Study Phase: Phase 2
View 3 Less Clinical Trials

54 Total Publications

PolyGenie: a reproducible Nextflow pipeline for phenome-wide association studies using polygenic risk scores.
PolyGenie: a reproducible Nextflow pipeline for phenome-wide association studies using polygenic risk scores.
Journal: NAR genomics and bioinformatics
Published: March 05, 2026

Frequently Asked Questions about Xavier G. Farre

Is Xavier G. Farre a top-rated expert for Lymphangioleiomyomatosis?

MediFind is an objective health platform that identifies experts based on real-world data. Xavier G. Farre is classified as an Experienced expert for Lymphangioleiomyomatosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Xavier G. Farre participate in research or clinical trials?

Yes. Xavier G. Farre has published 54 articles and abstracts on conditions like Lymphangioleiomyomatosis. You can view a list of Xavier G. Farre's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Farre's expertise for a condition
ConditionClose
        View All 15 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile